Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 602 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ILD Clear all
Completed No phase listed Observational

Beneficial Effects of Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis

NCT01107028
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Standard pulmonary rehabilitation program
Other
Lead sponsor
National Jewish Health
Other
Eligibility
40 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 17, 2026, 5:57 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

NCT06012500
View directory record Official record
Conditions
ILD
Interventions
Xenon-129
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 90 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 17, 2026, 5:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immunological Characterization of Bronchoalveolar Cells in Normals

NCT00843414
View directory record Official record
Conditions
Lung Disease
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
1,232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1978 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 7, 2016 · Synced Oct 17, 2026, 5:57 PM EDT
Terminated No phase listed Observational

A Study of Patients With Chronic Disease

NCT04263727
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, IPF, COPD, Respiratory Disease
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
Not listed
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Colorado Springs, Colorado • Clearwater, Florida • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 17, 2026, 5:57 PM EDT
Enrolling by invitation Phase 2 Interventional

Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

NCT06751602
View directory record Official record
Conditions
Rejection Chronic Renal
Interventions
Belumosudil 200 mg QD, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 17, 2026, 5:57 PM EDT
Not yet recruiting Not applicable Interventional

MOBoxy: MoblO2 to Maintain Oxygenation

NCT07222592
View directory record Official record
Conditions
COPD, Interstitial Lung Disease
Interventions
MoblO2 control
Device
Lead sponsor
National Jewish Health
Other
Eligibility
25 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis

NCT00563212
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
aerosol interferon-gamma
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 17, 2026, 5:57 PM EDT
Terminated Not applicable Interventional Results available

Telenursing and Remote Monitoring in Idiopathic Pulmonary Fibrosis (IPF)

NCT03562247
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Usual Care of IPF, Telenursing, Telenursing and Remote Monitoring
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Study of Nicotine Patches in Patients With Sarcoidosis

NCT00701207
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
nicotine patch
Drug
Lead sponsor
Elliott Crouser MD
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 17, 2026, 5:57 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility of a Medical-Legal Partnership Model to Connect Coal Miners QuitAid

NCT07694492
View directory record Official record
Conditions
Tobacco Use Cessation, Tobacco Use Disorder, Nicotine Dependence, Smokeless Tobacco Use
Interventions
QuitAid (pharmacist-delivered MTM), Nicotine Replacement Therapy (NRT)
Behavioral · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 17, 2026, 5:57 PM EDT
Recruiting Phase 1 Interventional

Dose-Escalation Study of Artesunate Patients With IPF

NCT05988463
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Artesuante, Placebo capsules
Drug · Other
Lead sponsor
Joseph C. Wu
Other
Eligibility
40 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 17, 2026, 5:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in the Evaluation of Chronic Lung Disease

NCT00926523
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension, Interstitial Lung Disease
Interventions
Blood Gas, Pulmonary Exercise Test, Spirometry, Breath Condensate Collector
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2011 · Synced Oct 17, 2026, 5:57 PM EDT
Recruiting Not applicable Interventional

SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers

NCT07269262
View directory record Official record
Conditions
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions
SUPPORT-T Educational Intervention
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 4 Interventional Results available

Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment

NCT02788474
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
nintedanib, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Jasper, Alabama • Danbury, Connecticut • Clearwater, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 17, 2026, 5:57 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pulmonary Fibrosis Foundation Community Registry

NCT05382572
View directory record Official record
Conditions
Pulmonary Fibrosis, Interstitial Lung Disease, Lung Fibrosis, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
Pulmonary Fibrosis Foundation
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 17, 2026, 5:57 PM EDT
Recruiting Phase 2Phase 3 Interventional

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

NCT06328777
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma, Interstitial Lung Diseases
Interventions
CABA-201
Biological
Lead sponsor
Cabaletta Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
New Haven, Connecticut • Jacksonville, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH

NCT00588536
View directory record Official record
Conditions
Langerhans Cell Histiocytosis
Interventions
Methotrexate, 6-Thioguanine, Leucovorin Calcium
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Mitigation of Radiation Pneumonitis and Fibrosis

NCT01754909
View directory record Official record
Conditions
Lung Cancer, Radiation Pneumonitis
Interventions
Enalapril, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 17, 2026, 5:57 PM EDT
Suspended Phase 3 Interventional

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07181382
View directory record Official record
Conditions
Pulmonary Hypertension Associated With Interstitial Lung Disease
Interventions
Placebo, Seralutinib, Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Fresno, California • Albuquerque, New Mexico • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 17, 2026, 5:57 PM EDT
Active, not recruiting No phase listed Observational

A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis

NCT04844359
View directory record Official record
Conditions
Hypersensitivity Pneumonitis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 85 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Tucson, Arizona • Sacramento, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 17, 2026, 5:57 PM EDT
Withdrawn Phase 4 Interventional

Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil

NCT00625079
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Hypertension
Interventions
sildenafil
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial

NCT02874989
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Dasatinib + Quercetin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Winston-Salem, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 17, 2026, 5:57 PM EDT
Not listed No phase listed Observational

Interstitial Lung Disease in Early Rheumatoid Arthritis

NCT03977415
View directory record Official record
Conditions
Rheumatoid Arthritis, Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 90 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 17, 2026, 5:57 PM EDT
Terminated Phase 2 Interventional

Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease

NCT05079126
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Trans Sodium Crocetinate, Placebo
Drug
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
30 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 17, 2026, 5:57 PM EDT